CGEM news

Cullinan Therapeutics will present updated Phase 1 data for CLN-049 and velinotamig (CLN-803) across four posters at the 68th ASH Annual Meeting in December, highlighting potential safety and therapeutic efficacy.

Cullinan announced an NDA submission for zipalertinib in combination with chemotherapy under the FDA Real-Time Oncology Review program based on Phase 3 clinical data, with milestones potentially worth $100 million pending approval.

Cullinan Therapeutics announced four major updates for Q4 2026 across its T cell engager pipeline, including multi-dose SLE data for CLN-978 in December and Phase 1 updates for velinotamig in November and CLN-049 in December.

Cullinan reported positive Phase 3 REZILIENT3 results where zipalertinib plus chemotherapy significantly improved progression-free survival in first-line EGFR exon 20 insertion NSCLC. The data, presented at WCLC, supported the therapy's efficacy. These results are highly relevant for the company's p…

Cullinan Therapeutics released Q2 results and shared clinical data, including plans to begin a potentially registrational Phase 2 study for CLN-049 and confirm Phase 2 expansions for CLN-978 and velinotamig by early 2027.

Cullinan Therapeutics reported encouraging Phase 1 clinical data for its CD19 and BCMA T cell engager programs targeting autoimmune diseases, with CLN-978 showing remissions in SLE and RA patients. The data supports advancement into additional indications and represents a potential paradigm shift in…

Cullinan Therapeutics announced initial clinical data for CLN-978, a CD19xCD3 T cell engager, demonstrating remissions in lupus and rheumatoid arthritis patients with a favorable safety profile. The positive Phase 1 results support advancement of the drug through clinical development for autoimmune …

Cullinan Therapeutics announced initial clinical data from two Phase 1 studies of CLN-978, a CD19xCD3 T cell engager, showing favorable safety profile and robust B cell depletion with early signals of clinical activity in treatment-refractory rheumatoid arthritis and systemic lupus erythematosus pat…